key: cord-0825055-fuhrfovk authors: Chauhan, Sanshriti; Meshram, Hari Shankar; Kute, Vivek; Patel, Himanshu; Desai, Sudeep; Dave, Ruchir title: Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India date: 2021-10-06 journal: Transpl Infect Dis DOI: 10.1111/tid.13735 sha: c4c32815bc445f934678a846e75213cf88b4a346 doc_id: 825055 cord_uid: fuhrfovk INTRODUCTION: Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported. METHODS: We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed. RESULTS: The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%). The most common persistent symptom was fatigue which significantly decreased in the follow‐up (n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up (n = 4, 3% vs. 7, 5% vs. 3, 2%; p‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline. CONCLUSION: Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up. protocol for post-COVID-19 follow-up and rehabilitation clinic. A recent study raised concerns about chronic COVID-19 in patients on chronic immunosuppression. 11 The questions which need to be answered are as follows: What is the burden and spectrum of persistent symptoms in the transplant population? How does COVID-19 affect the quality of life of kidney transplant recipients (KTR) in followup? What is the long-term graft outcome of COVID-19-recovered KTR? Are there any multisystem complications during follow-up? Thus, we investigated the short-term and long-term follow-up course of hospitalized KTR discharged from our center. The novelty of this study lies in the fact that comprehensive follow-up of COVID-19recovered KTR has been scantly described in the literature so far. This study will further help transplant physicians across the world in understanding SARS-CoV-2 sequelae and guide them in further planning and management for potential future waves. This is a retrospective cohort study conducted from May 2020 to The institutional protocol was to do a follow-up at 1-month, 3-month, and beyond 6 months. A dedicated team of doctors conducted the follow-up of discharged patients through telephonic and in-person visits as feasible. A comprehensive evaluation of physical, clinical, and psychological domains was done on follow-up visits. Routine tests which include complete blood counts, random blood sugar, blood urea, serum creatinine, electrocardiogram, and liver functions test were done in all cases. Urine analysis was performed in every visit for detection of any new onset hematuria or albuminuria. In the case of a sensitized patient, donor-specific antibody (DSA) testing was done. DSA testing was done cases with incomplete recovery (declining creatinine but not reaching baseline) of acute kidney injury (AKI) in follow-up. Cytomegaloviruses, BK polyomavirus (BKV), Epstein Barr virus, Parvovirus B19 were screened for the cases which had concomitant viral infections with COVID-19 or had a history of these viral infections in past. Repeat Chest x-ray was done for all in the first follow-up visit and on subsequent visits based on any symptoms. A repeat high resolution computed tomography (HRCT) thorax was done only in cases with complaints of breathing difficulty or worsening report in chest imaging done in the follow-up. nRT-PCR repeat testing was not mandatory, and there was no fixed protocol on the timing of a repeat test, as it was logistically not possible and clinically not meaningful. For measuring the quality of life, EuroQoL5-dimension score (EQ-5D-5L) 13 and EuroQoL visual analogue score (EQVAS) score were used. The modified medical research council 14 scale (mMRC) for breathlessness was used for assessing dyspnoea. In patients scoring poorly on mMRC scale, pulmonary function tests were done. In case of any significant psychiatric problems, patients underwent counselling and were referred to the psychiatry unit for expert review and further management. For analysis of data, patients were grouped based on the duration of follow-up, and three groups were formed: 1-month, 3-month, and ≥6 months follow-up. Categorical data were expressed as numbers and percentages in parenthesis, and continuous data were expressed as mean, range, median, standard deviation, and interquartile range (IQR). A t-test was used to compare the median baseline creatinine of graft loss and normal grafts in the cohort. The three group variables were compared with the analysis of variance (ANOVA) test for parametric variables and the Kruskal-Wallis test for non-parametric variables. For assessing the graft outcome, a spaghetti plot, scatter plot, Kaplan-Meier plot, and box whisker plots are derived. A two-tailed p-value of less than 0.05 was considered statistically significant. Statistical analysis was done using IBM SPSS 21 software. From May 2020 to December 2020, a total of 142 KTR with COVID-19 were discharged of whom the follow-up was done from discharge to 27 July 2021. A total of 139, 134, and 128 KTR completed 1-month, 3-month, and ≥6-month follow-up, respectively. The median (IQR) follow-up F I G U R E 1 Summary of the cases duration of the cohort was 9 (8-11) months. Figure 1 summarizes the course of the study. One case died at home before 1 month of discharge. Two deaths occurred as aspergillus pneumonia within 3 months. One case of re-infection resulted in death. Two deaths occurred as post-COVID-19 mucormycosis. 15 There were no admissions for the viral infections which were screened in selected cases. Tables S1 and S2 demonstrate the baseline and demographic features of the cohort and acute COVID-19 course, respectively. The median age of the cohort was 42 (32-49) years with a predominance of male sex (84%). The bulk of the cohort was live-related transplants (n = 120, 84%) and only a few cases (n = 22, 16%) presented with COVID-19 within 1 year of transplantation. The comorbid conditions reported were hypertension (n = 104, 73%) as the most common followed by diabetes (n = 33, 23%), heart disorders (n = 14, 9.8%), and obesity (n = 30, 21%). The COVID-19 severity during the admission spanned from asymptomatic (n = 9, 4%), mild (n = 71, 50%), moderate (n = 46, 35%) to severe (n = 18, 12%). The cohort had no mechanical ventilation cases, as all admissions with mechanical ventilation had mortality. Radiological changes (n = 96, 68%) were observed in most of the cases. Allograft dysfunction (n = 64, 45%) was reported in almost half of the cases. Most patients were treated with steroids (n = 64, 45%) and remdesivir (n = 63, 44%). Antimetabolite was discontinued (n = 108, 72%) or reduced (n = 31, 22%) in most of the cohort. Calcineurin inhibitors (CNIs) was stopped (n = 19, 16%) or reduced (n = 26, 21%) in moderate to severe cases. The protocol for the timing of reintroduction for antimetabolite was 7-10 days post-discharge, while CNI was resumed on the day of discharge in a half dose. Clinical symptoms post-discharge p-value = 0.002) which were the main symptoms at 1-month resolved significantly at longer follow-up. Overall, there were very less symptoms at extended follow-up. Disturbed sleep (n = 9, 6.6%) and appetite loss (n = 7, 5.1%) were most common symptom at ≥6-month follow-up. (20) 10 (14) 15 ( Table 2 describes the summary of cases with graft losses or rejection. Sixty-four (45%) cases developed AKI during COVID-19 admission, of The study reports the follow-up outcome of SARS-CoV-2 survivors in KTR. Initially, when reports of COVID sequelae were published, we decided to do the follow-up of recovered patients, a dedicated team of doctors was assigned for follow-up of the patients. We explore here the follow-up course of post-transplant SARS-CoV-2 survivors with all grades of severity and duration of follow-up from 1 month to more than 6 months. The authors have previously documented the acute COVID-19 course of KTR from the center. 16 Even in mild cases, there are reports of persistent symptoms. [17] [18] [19] The most common persistent symptoms in our study were fatigue and malaise as reported in the general population. Chronic fatigue syndrome (CFS) has been linked with survivors of the SARS pandemic, 20 but it was not observed in our study in COVID-19. The symptoms and signs resolved before 6 months, so none fulfilled the criteria for CFS. As contrary to concerning reports of persistent cough, breathlessness previously described in general patients, we did not find any evidence of these persistent symptoms in our study. Our report is similar to the long-term report of a 6-month follow-up of a large study from China. 21 Duration from the onset of COVID-19 symptoms to symptom-free was 14 days. In our report, there were no complaints of parosmia or anosmia at 1-month discharge unlike reported in the We did a subjective screening through mMRC, clinical screening, and a repeat x-ray chest at a regular follow-up to rule out any evidence of pulmonary fibrosis, and hence the likelihood of missing pulmonary fibrosis cases is less. A large population-based study has reported neurological and psychiatric manifestations in COVID-19 survivors. 34 In our cohort, there were no neurological events like stroke, new-onset tremor disorder, or Parkinsonism. We did not specifically screen for a possibility of the thromboembolic episode, but there were no such obvious reports during the study period. The strength of the study is enlisted. Firstly, this is the first study of its kind in KTR to describe the follow-up course of post-COVID-19. Secondly, a large sample size was studied, so the applicability of results in other settings is considerable. Thirdly, all grades of COVID-19 severity were explored, so the study can be interpolated for asymptomatic to critical cases. Fourthly, we did not fix a particular time frame to collect data, so the results encompass follow-up duration of diverse lengths, which further adds to the power of the study. The study has few inherent and worth mentioning limitations. Firstly, the sample size was small, and also the number of severe and critical cases was relatively less in the cohort, so the results should be very cautiously applied in severe cases. Secondly, the study did not objectively assess for pulmonary functions or thromboembolic phenomena. However, no clinical symptoms in follow-up were suggestive of such complications. There could be also some reporting bias in the subjective assessment. Thirdly, protocol biopsy was not done in acute COVID-19 to see any direct effect of the virus in the graft. The justification behind this was the initial observations of recovering graft shortly after discharge; hence we waited for the kidney function to normalize within few weeks of discharge. Fourthly, the immune response to COVID-19 was not studied. We describe the largest cohort of SARS-CoV-2 sequelae in KTR with the longest follow-up of 9 (8-11) months. Fatigue was the most prominent symptom post-discharge. Oxygen requiring cases had poorer quality of life compared to non-oxygen requiring cases, but the assessment scores significantly improved during the follow-up course. Ten graft losses reported were mostly in patients with chronic graft dysfunction. Our initial reports are having reassuring outcomes. Still, these are early days to cut loose, and the follow-up studies should be continued in the transplant population to avoid any possible complications till further high-level scientific data are available. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis A US population health survey on the impact of COVID-19 using the EQ-5D-5L Long-COVID Syndrome? A study on the persistence of neurological, psychological, and physiological symptoms Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review Kidney transplant recipients infected by COVID-19: Review of the initial published experience COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: a systematic review of cases Is COVID-19 infection more severe in kidney transplant recipients? Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: a multicenter cohort study from India Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19 in transplant recipients: the Spanish experience Researchers tie severe immunosuppression to chronic COVID-19 and virus variants Clinical management protocol: covid-19. Government of India Ministry of Health & Family Welfare Directorate General of Health Services (EMR Division) The construct and concurrent validity of the EQ-5D in a renal transplant population Evaluation of clinical methods for rating dyspnea Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in followup Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: a retrospective cohort from a developing nation Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers Follow-up of adults with noncritical COVID-19 two months after symptom onset Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-center longitudinal study Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Six month follow-up of selfreported loss of smell during the COVID-19 pandemic Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria COVID-19-associated kidney injury: a case series of kidney biopsy findings Recovery of kidney function after AKI due to COVID-19 in kidney transplant recipients Invasive fungal infections in renal transplant patients: a single center study Successful management of dengue in renal transplant recipients: a retrospective cohort from a single center Follow-up study of the chest CT characteristics of COVID-19 survivors seven months after recovery Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge Six-month follow-up chest CT findings after severe COVID-19 pneumonia Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Long-term follow-up of SARS-CoV-2 recovered renal transplant recipients: A single-center experience from India We would like to express our sincere gratitude to the hospital staff for their committed efforts in managing the patients during the COVID-19crisis. The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.